2009 Annual Meeting | Evaluation and Management of Autonomic Disorders

Date Wednesday 04/29/09

Time 02:15 PM - 06:00 PM Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program is not expected to be available in the meeting's On Demand product.

Event Type PM Half-Day Course

Director(s) Thomas C. Chelimsky, MD

Topic(s)

Learning Objectives Participants should be able to enhance their ability to formulate a differential diagnosis, organize a work-up, and offer a treatment plan for patients with common varieties of autonomic dysfunction.

CME Available No CME available

Core Competencies Medical Knowledge

Program Level Advanced

Recommended Audience Practitioner, Fellow, Academician, Resident, Nurse

Event Timeline
02:15 PM - 02:25 PM		Overview and Classification of Dysautonomias Thomas C. Chelimsky, MD
02:25 PM - 03:05 PM		Autonomic Peripheral Neuropathies Roy L. Freeman, MD
03:05 PM - 03:45 PM		Postural Tachycardia Syndrome Paola Sandroni, MD, PhD, FAAN
03:45 PM - 04:00 PM		Break
04:00 PM - 04:40 PM		Orthostatic Hypotension Thomas C. Chelimsky, MD
04:40 PM - 05:20 PM		Thermoregulatory Disorders William P. Cheshire, Jr., MD, FAAN
05:20 PM - 06:00 PM		Discussion of Cases from the Audience and Faculty: Question and Answers

Faculty Disclosures
Thomas C. Chelimsky, MD	Dr. Chelimsky has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Proctor & Gamble. Dr. Chelimsky has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Various Legal Firms. Dr. Chelimsky has received personal compensation in the range of $5,000-$9,999 for serving as an Expert Witness for Various Legal Firms. Dr. Chelimsky has received stock or an ownership interest from PainSTakers, LLC. The institution of Dr. Chelimsky has received research support from NIDDK. The institution of Dr. Chelimsky has received research support from Advancing a Healthier Wisconsin.
Roy L. Freeman, MD	Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Regenacy. Dr. Freeman has received personal compensation in the range of $100,000-$499,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Neurobo. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Vertex. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli-Lilly. Dr. Freeman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Theravance. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Inhibikase. Dr. Freeman has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Freeman has stock in Neurobo. Dr. Freeman has stock in Cutaneous NeuroDiagnostics. The institution of Dr. Freeman has received research support from NIH. The institution of Dr. Freeman has received research support from Theravance. The institution of Dr. Freeman has received research support from Biohaven. The institution of Dr. Freeman has received research support from Lundbeck.
William P. Cheshire, Jr., MD, FAAN	Dr. Cheshire has received personal compensation in the range of $500-$4,999 for serving as a Consultant for oxford university press. Dr. Cheshire has a non-compensated relationship as a Associate Editor with Clinical Autonomic Research that is relevant to AAN interests or activities.
Paola Sandroni, MD, PhD, FAAN	Dr. Sandroni has nothing to disclose.

��ɫ��

��ɫ��